[{"NetIncomeLossConverted_1_Q3_USD":-84609000.0,"NetIncomeLossConverted_3_Q3_USD":-193016000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-108889000.0,"CommonStockSharesOutstanding_0_Q3_shares":126991631.0,"StockholdersEquity_0_Q3_USD":812355000.0,"EarningsPerShareBasic_1_Q3_USD":-0.67,"EarningsPerShareBasic_3_Q3_USD":-1.66,"Assets_0_Q3_USD":943259000.0,"CommonStockSharesConverted_0_Q3_shares":126991631.0,"RevenuesConverted_1_Q3_USD":1928000.0,"RevenuesConverted_3_Q3_USD":74634000.0,"Ticker":"VIR","CIK":"1706431","name":"VIR BIOTECHNOLOGY, INC.","OfficialName":"Vir Biotechnology Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3076942595.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201110"}]